Board of directors

Anders Williamsson Chairman and B.Sc. (Econ.)

30 years’ of international experience of medical technology and life sciences. Anders has held senior executive positions in several companies, and has been resident and worked in the US and the UK. He was born in 1954 and has been Chairman of Aerocrine since March 2007. Anders is also Chairman of Jolife AB, Glycorex Transplantation AB (publ), Nano Bridging Molecules SA, Biomain AB, AAA Teamwork AB, Provinsbanken in Helsingborg, Sweden and Fade Hook & Draw AB. He is also a Board member of Ambu A/S, Foss A/S, Tigran Technologies AB. His previous professional experience includes CEO and Board member of HemoCue AB, HemoCue Holding AB and POCT Holding AB, CEO of HemoCue Inc., Atos Medical AB and Vice President of Pernovo AB.
Aerocrine shareholding: 22,500

Lars Gatenbeck Board member

Board member, M.D., professional experience includes President and CEO of the Karolinska Hospital and senior executive positions in Pharmacia & Upjohn. Lars was born in 1956, and has been a Board member of Aerocrine since 2001. He is also Chairman of Life Equity Group, Chairman and CEO of H&B Capital Advisors AB and Life Equity Advisors AB, Chairman of CellaVision AB, Swecare and Life Medical AB and board member of Cancerföreningen and Aleris. Lars is a former Chairman of Aerocrine and has been a Board member of companies including Investment AB Öresund, Biotage AB, Neoventa Medical AB and Perbio Science.
Aerocrine shareholding: 0

Lars Gustafsson Board member

Board member, M.D., Professor of Physiology at the Department of Physiology and Pharmacology at the Karolinska Institute. He is a co-founder of Aerocrine and has published over 130 papers on physiology and environmental medicine. Lars was born in 1950 and has been a Board member of Aerocrine since incorporation in 1997. Lars is active in research into the mechanisms underlying the formation of nitric oxide (NO) in the airways and mechanisms identified with asthma. Lars is the CEO and Board member of Attgeno AB, Nitrograf Bioanalysis AB, was a partner of Nitricare Handelsbolag and has led research groups that participated in the production of material for the Swedish National Allergy Commission, and for the Swedish Environmental Protection Agency. He was awarded the Environmental Medicine Prize from the Swedish Cancer & Allergy Foundation in 1999.
Aerocrine shareholding: 269,449  and warrants corresponding to 211,092 shares.

Staffan Lindstrand Board member

Board member since 1999. M.Sc. (Eng.), partner with HealthCap and possesses extensive experience of venture capital in life sciences, and before that, investment banking. He is a Board member of HealthCap AB, and companies including Biotage AB, Orexo AB and Technolas Perfect Vision GmbH.
Aerocrine shareholding: 0.

Magnus Lundberg Board member

Board member, M.Sc. in biology and biochemistry. Magnus was born in 1956 and has been a Board member of Aerocrine since 2002. He is CEO and President of the Phadia group. Magnus is a Board member of Onyx Pharmaceuticals Inc. (of the US).
Aerocrine shareholding: 67,500

Yvonne Mårtensson Board Member

Board member since April 2009. Yvonne is since 1998 the CEO of CellaVision AB and possesses more than 25 years experience of international sales and marketing in fast-growing companies at different stages. Yvonne is also a board member in Biolin Scientific AB. Previous experience includes HemoCue AB where Yvonne among other things was the head of sales and marketing in the US.
Aerocrine shareholding: 0

Karl Swartling Board member

Born 1965. Board member since 2004.
Karl Swartling is Managing Director and Co-Head of Investor Growth Capital Europe (Stockholm). Karl also serves on the Board of NeuroNova AB, Affibody Holding AB and Global Health Partner AB and is deputy board member in Atlas Antibodies AB, Tobii Technologies AB and Cambio Healthcare Systems AB. Karl spent 15 years with the McKinsey & Company consulting firm with main focus on Life Science. Karl Swartling holds an MBA from the Stockholm School of Economics.
Aerocrine shareholding: 7,500